Exploring Amgen's Earnings Expectations
Amgen (NASDAQ:AMGN) is preparing to release its quarterly earnings on Tuesday, 2026-02-03. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Amgen to report an earnings per share (EPS) of $4.75.
The announcement from Amgen is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
Historical Earnings Performance
During the last quarter, the company reported an EPS beat by $0.63, leading to a 7.81% increase in the share price on the subsequent day.
Here's a look at Amgen's past performance and the resulting price change:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | 5.01 | 5.27 | 4.3 | 5.08 |
| EPS Actual | 5.64 | 6.02 | 4.9 | 5.31 |
| Price Change % | 8.00 | -5.00 | -1.0 | 7.00 |
Stock Performance
Shares of Amgen were trading at $341.88 as of January 30. Over the last 52-week period, shares are up 18.68%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release.
Analysts' Perspectives on Amgen
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Amgen.
A total of 12 analyst ratings have been received for Amgen, with the consensus rating being Neutral. The average one-year price target stands at $339.0, suggesting a potential 0.84% downside.
Comparing Ratings with Competitors
The below comparison of the analyst ratings and average 1-year price targets of Gilead Sciences, Vertex Pharmaceuticals and Regeneron Pharmaceuticals, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.
- Analysts currently favor an Buy trajectory for Gilead Sciences, with an average 1-year price target of $146.55, suggesting a potential 57.13% downside.
- Analysts currently favor an Outperform trajectory for Vertex Pharmaceuticals, with an average 1-year price target of $517.86, suggesting a potential 51.47% upside.
- Analysts currently favor an Buy trajectory for Regeneron Pharmaceuticals, with an average 1-year price target of $812.71, suggesting a potential 137.72% upside.
Comprehensive Peer Analysis Summary
The peer analysis summary presents essential metrics for Gilead Sciences, Vertex Pharmaceuticals and Regeneron Pharmaceuticals, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.
| Company | Consensus | Revenue Growth | Gross Profit | Return on Equity |
|---|---|---|---|---|
| Amgen | Neutral | 12.40% | $6.47B | 37.73% |
| Gilead Sciences | Buy | 2.97% | $6.20B | 14.81% |
| Vertex Pharmaceuticals | Outperform | 10.99% | $2.66B | 6.28% |
| Regeneron Pharmaceuticals | Buy | 3.46% | $3.23B | 2.72% |
Key Takeaway:
Amgen ranks highest in Gross Profit and Return on Equity among its peers. It is in the middle for Revenue Growth.
Delving into Amgen's Background
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Amgen: Financial Performance Dissected
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Amgen displayed positive results in 3 months. As of 30 September, 2025, the company achieved a solid revenue growth rate of approximately 12.4%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 33.65%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Amgen's ROE excels beyond industry benchmarks, reaching 37.73%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 3.61%, the company showcases effective utilization of assets.
Debt Management: With a high debt-to-equity ratio of 5.67, Amgen faces challenges in effectively managing its debt levels, indicating potential financial strain.
To track all earnings releases for Amgen visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
